High‑risk, high‑reward stocks appeal to investors who can handle sharp swings in price. These companies are still early in their growth journeys, but if their key catalysts play out, the returns can be explosive. According to analysts, three names worth considering now are Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMRX).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
These stocks were identified using the TipRanks Stock Screener tool. All three stocks have a Strong Buy consensus rating from analysts and an upside potential of over 200% in the next 12 months.
1. Kura Oncology (KURA)
Kura Oncology is developing targeted cancer drugs for patients with specific genetic profiles. The company’s lead programs focus on blocking cancer‑driving pathways found in aggressive tumors. Early data have been encouraging, and analysts think upcoming clinical results could be major catalysts for the stock.
The upside is meaningful, but risks remain. Drug development is unpredictable, and setbacks in trials or regulatory delays could hit the stock hard. Still, if Kura delivers strong data, analysts believe the shares could move sharply higher.
Turning to Wall Street, KURA stock has a Strong Buy consensus rating based on nine Buys and one Hold assigned in the last three months. At $28.13, the average Kura Oncology stock price target implies upside potential of 218.57%.
2. Angel Studios (ANGX)
Angel Studios, the company behind The Chosen and other crowdfunded hits, is building an entertainment model driven by its community. Instead of relying on traditional studios, Angel uses fan-funded projects and low-budget production to create shows and films that already have built‑in audiences. The approach is unconventional, but early success has drawn investor attention.
The model still comes with risk. Entertainment is hit-driven, and a few weak releases could hurt revenue. But if Angel continues to scale its fan-funded strategy and attract creators looking for alternatives to Hollywood’s traditional system, analysts see meaningful long-term upside.
Wall Street’s consensus rating for ANGX stock is Strong Buy based on six unanimous Buys. The average analyst price target of $7.83 implies an upside potential of 217.65% from current levels.
3. Immuneering (IMRX)
Immuneering is developing a new type of cancer medicine designed to shut down cancer‑driving pathways at the molecular level. Its lead drug targets the RAS/MAPK pathway, one of the most important and historically toughest areas in oncology.
The company is still in the early stages, which means high volatility and long timelines. Progress will take time, and setbacks are always possible. But if Immuneering proves its approach works, analysts say the scientific upside could be significant.
On TipRanks, analysts have a Strong Buy consensus rating on IMRX stock based on six Buys assigned in the past three months. Further, the average Immuneering price target of $17.00 per share implies 204.66% upside potential.
